Farma-Biotech’s collaboration program, which promotes collaboration in the pharmaceutical industry with small biotech companies, academia, hospitals and R&D, celebrates five years of great success in Spain.
During this period, they have selected one hundred potentially suitable projects for the development of new medicines and therapeutic solutions, from amongst more than 400 received proposals. Trade group Farmaindustria launched this initiative in 2011 with the aim to provide the necessary information and boost potential collaborations with pharmaceutical companies, with both public and private stakeholders.
The meeting ‘ Good practices in the Farma-Biotech program,’ in the context of Biospain 2016, will be held in Bilbao on Friday September 30, from 09.00 to 12.00. It aims to take stock of the work carried out at this time and review, and spread, some of the best practices developed in this initiative. In the course of this session participants will learn, in detail, the point of view of all public and private stakeholders involved in this project. For the roundtable, it is expected that, María Aguirre; director of Research and Health Innovation of the Basque Government, Anabel Sanz; director of technology transfer National Cancer Research Center (CNIO) and representatives of pharmaceutical companies and biotechnology companies, will all participate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze